{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:06:43Z","timestamp":1783980403496,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-05159-y","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:45:48Z","timestamp":1783745148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-MAG-associated neuropathy: a case report and literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Dachuan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"issue":"4","key":"5159_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/jnnp-2024-334678","volume":"96","author":"YG Min","year":"2025","unstructured":"Min YG, Visentin A, Briani C, et al. Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and management. J Neurol Neurosurg Psychiatry. 2025;96(4):340\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"5159_CR2","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3390\/brainsci14121294","volume":"14","author":"G Siconolfi","year":"2024","unstructured":"Siconolfi G, Vitali F, Sciarrino MA, et al. IgM Flare in Anti-MAG neuropathy post rituximab treatment: a clinical case and a systematic review of the literature. Brain Sci. 2024;14(12):1294.","journal-title":"Brain Sci"},{"issue":"4","key":"5159_CR3","first-page":"e81946","volume":"17","author":"R Pein","year":"2025","unstructured":"Pein R, Steinberg A. Treatment of Anti-Myelin-Associated Glycoprotein (MAG) Antibody Neuropathy Using Zanubrutinib in a Patient With Waldenstr\u00f6m Macroglobulinemia: A Clinical Vignette. Cureus. 2025;17(4):e81946.","journal-title":"Cureus"},{"issue":"1","key":"5159_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3988\/jcn.2023.0127","volume":"20","author":"YG Min","year":"2024","unstructured":"Min YG, Han HJ, Shin HY, et al. Therapeutic Outcomes and Electrophysiological Biomarkers in Anti-Myelin-Associated Glycoprotein Neuropathy: A Multicenter Cohort Study in South Korea. J Clin Neurol. 2024;20(1):50\u20138.","journal-title":"J Clin Neurol"},{"issue":"4","key":"5159_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/bloodadvances.2024014115","volume":"9","author":"BM Heyman","year":"2025","unstructured":"Heyman BM, Opat SS, Wahlin BE, et al. Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenstr\u00f6m macroglobulinemia. Blood Adv. 2025;9(4):722\u20138.","journal-title":"Blood Adv"},{"issue":"11","key":"5159_CR6","doi-asserted-by":"publisher","first-page":"e210000","DOI":"10.1212\/WNL.0000000000210000","volume":"103","author":"CJ Klein","year":"2024","unstructured":"Klein CJ, Triplett JD, Murray DL, et al. Optimizing anti-myelin-associated glycoprotein and IgM-gammopathy testing for neuropathy treatment evaluation. Neurology. 2024;103(11):e210000.","journal-title":"Neurology"},{"issue":"20","key":"5159_CR7","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.2169\/internalmedicine.4785-24","volume":"64","author":"C Yuzawa","year":"2025","unstructured":"Yuzawa C, Tajiri M, Usuda M, et al. Treatment of Anti-myelin-associated glycoprotein neuropathy with tirabrutinib and a 3-year follow-up. Intern Med. 2025;64(20):3039\u201343.","journal-title":"Intern Med"},{"issue":"10","key":"5159_CR8","doi-asserted-by":"publisher","first-page":"e10928","DOI":"10.1016\/j.heliyon.2022.e10928","volume":"8","author":"H Yasuda","year":"2022","unstructured":"Yasuda H, Tomizawa Y, Harada S, et al. Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib. Heliyon. 2022;8(10):e10928.","journal-title":"Heliyon"},{"issue":"9","key":"5159_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/jnnp-2020-325868","volume":"92","author":"M Ruiz","year":"2021","unstructured":"Ruiz M, Puthenparampil M, Campagnolo M, et al. Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies. J Neurol Neurosurg Psychiatry. 2021;92(9):969\u201374.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"5159_CR10","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jaad.2025.05.1374","volume":"93","author":"S Cao","year":"2025","unstructured":"Cao S, Yang B, Wang Z, et al. Efficacy, safety, and B-cell depletion capacity of 3 rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: A 52-week clinical trial. J Am Acad Dermatol. 2025;93(3):634\u201343.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"5159_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood.2021013393","volume":"139","author":"YJ Wu","year":"2022","unstructured":"Wu YJ, Liu H, Zeng QZ, et al. All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2022;139(3):333\u201342.","journal-title":"Blood"},{"issue":"7","key":"5159_CR12","first-page":"CD014574","volume":"7","author":"KC Dodd","year":"2025","unstructured":"Dodd KC, Clay FJ, Forbes AM, et al. Rituximab for myasthenia gravis. Cochrane Database Syst Rev. 2025;7(7):CD014574.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"5159_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/jnnp-2017-316715","volume":"89","author":"J Svahn","year":"2018","unstructured":"Svahn J, Petiot P, Antoine JC, et al. Francophone anti-MAG cohort Group. Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry. 2018;89(5):499\u2013505.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5159_CR14","first-page":"578436","volume":"400","author":"G Mak","year":"2025","unstructured":"Mak G, Bennett D, Phan C, et al. Reversible rituximab demyelination in anti-MAG polyneuropathy: A role for IVIG? J Neuroimmunol. 2025;400:578436.","journal-title":"J Neuroimmunol"},{"key":"5159_CR15","first-page":"29","volume":"77","author":"S Kuwabara","year":"2025","unstructured":"Kuwabara S. Updated diagnosis and treatment for chronic inflammatory demyelinating polyradiculoneuropathy based on the EAN\/PNS guideline 2021. Brain Nerve. 2025;77:29\u201334.","journal-title":"Brain Nerve"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05159-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05159-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05159-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:02:12Z","timestamp":1783980132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05159-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5159"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05159-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"2 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the ethics committee of the First Naval Hospital of Southern Theatre Command, and all procedures complied with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of clinical data and electrophysiological findings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"454"}}